Drug interactions
Elranatamab + Metformin-repaglinide
Severity: Moderate
Elranatamab and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Elranatamab causes cytokine release syndrome, which can temporarily suppress CYP enzyme activity. This may raise repaglinide concentrations and the risk of hypoglycemia, mainly during step-up dosing and around CRS episodes.
What this interaction means in plain words
Elranatamab and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Elranatamab belongs to Oncology; Metformin-repaglinide belongs to Endocrine.
Why it happens
Cytokine-mediated suppression of CYP3A4 activity reduces repaglinide metabolism.
What to do
Monitor blood glucose during step-up dosing and for about two weeks after the first full dose, especially during CRS. Reduce the repaglinide dose if hypoglycemia occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elranatamab and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Elranatamab
- Elranatamab + Ergotamine Major
- Elranatamab + Pimozide Major
- Bendamustine + Elranatamab Moderate
- Carbamazepine + Elranatamab Moderate
- Clomipramine + Elranatamab Moderate
- Clozapine + Elranatamab Moderate
Frequently asked questions
Can I take Elranatamab with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Elranatamab and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Elranatamab causes cytokine release syndrome, which can temporarily suppress CYP enzyme activity. This may raise repaglinide concentrations and the risk of hypoglycemia, mainly during step-up dosing and around CRS episodes.
How serious is the interaction between Elranatamab and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose during step-up dosing and for about two weeks after the first full dose, especially during CRS. Reduce the repaglinide dose if hypoglycemia occurs.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
